GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » EV-to-FCF
中文

American Cryostem (American Cryostem) EV-to-FCF : -1.43 (As of Apr. 24, 2024)


View and export this data going back to 2010. Start your Free Trial

What is American Cryostem EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, American Cryostem's Enterprise Value is $1.17 Mil. American Cryostem's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.82 Mil. Therefore, American Cryostem's EV-to-FCF for today is -1.43.

The historical rank and industry rank for American Cryostem's EV-to-FCF or its related term are showing as below:

CRYO's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 4.22
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), American Cryostem's stock price is $0.0001. American Cryostem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.074. Therefore, American Cryostem's PE Ratio for today is At Loss.


American Cryostem EV-to-FCF Historical Data

The historical data trend for American Cryostem's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem EV-to-FCF Chart

American Cryostem Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 176.68 -91.16 -34.29 -42.90 -49.51

American Cryostem Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.81 -49.51 -37.05 -25.99 -18.17

Competitive Comparison of American Cryostem's EV-to-FCF

For the Biotechnology subindustry, American Cryostem's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Cryostem's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Cryostem's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where American Cryostem's EV-to-FCF falls into.



American Cryostem EV-to-FCF Calculation

American Cryostem's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.170/-0.818
=-1.43

American Cryostem's current Enterprise Value is $1.17 Mil.
American Cryostem's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Cryostem  (OTCPK:CRYO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

American Cryostem's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-0.074
=At Loss

American Cryostem's share price for today is $0.0001.
American Cryostem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.074.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


American Cryostem EV-to-FCF Related Terms

Thank you for viewing the detailed overview of American Cryostem's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


American Cryostem (American Cryostem) Business Description

Traded in Other Exchanges
N/A
Address
1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724
American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.
Executives
John S Arnone director, officer: Chairman 111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski director, officer: COO 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc. 10 percent owner 188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill 10 percent owner 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina director, 10 percent owner, officer: President and Director 1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915